Julie Lapenskie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julie Lapenskie has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- James Downar
Department of Medicine, University of Ottawa, Ottawa, ON, Canada
6 shared publications Koby Anderson
Bruyère Health Research Institute, Ottawa, Canada
4 shared publications- Peter Gerard Lawlor
Department of Medicine, Division of Palliative Care, University of Ottawa, Ottawa, Ontario, Canada
3 shared publications - Peter Tanuseputro
The University of Hong Kong
3 shared publications - Amy T. Hsu
Ottawa Hospital Research Institute Ottawa Ontario Canada
2 shared publications Anna Skold
Southeast Permanente Medical Group, Atlanta, Georgia, USA
2 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (6) , 363
Evaluating the Use of Tumor Bank DNA to Validate Genetic Factors Impacting Opioid Response in Patients with Advanced Cancer
Opioids are first-line therapy for cancer pain, yet up to 30% of patients fail to achieve adequate control at standard doses. Opioid response is partly genetically mediated, and understanding these factors may improve symptom management. This project aimed to assess the feasibility of using tumor bank DNA for pharmacogenetic analyses and to validate previously identified genetic variants associated with opioid response using existing genetic and clinical data. In this retrospective cohort study, clinical data (morphine equivalent daily dose, demographics) and genetic data (single-nucleotide polymorphisms) were analyzed across 31 candidate loci. Adult deceased patients with melanoma, colorectal, or lung cancer treated with opioids between 2016 and 2021 and with available tumor bank DNA were included. Patients without sufficient DNA or not deceased were excluded. Of 3503 potential samples, 502 met the inclusion criteria. The median morphine equivalent daily dose was 40 mg (range 1–2140 mg). Eleven loci across six genes may be associated with higher (OPRM1, TAOK3, NFKBIA, COMT, and RHBDF2) and lower (COMT and GCH1) opioid dose requirements (p < 0.05, not significant after Bonferroni correction). Ultimately, tumor bank DNA is a feasible resource for pharmacogenetic research. Identified loci may contribute to variability in opioid response and support future personalized pain management strategies.
- 17 June 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (6) , 363
Open AccessEvaluating the Use of Tumor Bank DNA to Validate Genetic Factors Impacting Opioid Response in Patients with Advanced Cancer
Opioids are first-line therapy for cancer pain, yet up to 30% of patients fail to achieve adequate control at standard doses. Opioid response is partly genetically mediated, and understanding these factors may improve symptom management. This project aimed to assess the feasibility of using tumor bank DNA for pharmacogenetic analyses and to validate previously identified genetic variants associated with opioid response using existing genetic and clinical data. In this retrospective cohort study, clinical data (morphine equivalent daily dose, demographics) and genetic data (single-nucleotide polymorphisms) were analyzed across 31 candidate loci. Adult deceased patients with melanoma, colorectal, or lung cancer treated with opioids between 2016 and 2021 and with available tumor bank DNA were included. Patients without sufficient DNA or not deceased were excluded. Of 3503 potential samples, 502 met the inclusion criteria. The median morphine equivalent daily dose was 40 mg (range 1–2140 mg). Eleven loci across six genes may be associated with higher (OPRM1, TAOK3, NFKBIA, COMT, and RHBDF2) and lower (COMT and GCH1) opioid dose requirements (p < 0.05, not significant after Bonferroni correction). Ultimately, tumor bank DNA is a feasible resource for pharmacogenetic research. Identified loci may contribute to variability in opioid response and support future personalized pain management strategies.
- Open Access
- 30 January 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (4) , 514-523
PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial
Background: Psychological distress is a common problem near the end of life, for which we lack effective, timely and scalable treatments. No previous study has assessed whether microdose psilocybin can improve symptoms in this population. Aim: To determine whether microdose psilocybin is safe, feasible and potentially efficacious in a palliative setting. Design: Open label, single-arm clinical trial of a 3-week oral psilocybin intervention, starting with 1 mg daily in week 1, increased to 2 mg in week 2 and 3 mg in week 3. ClinicalTrials.gov NCT04754061. Setting/participants: Two-center study in Ottawa, Canada of adults with advanced, incurable illness and an estimated prognosis of 1–12 months, experiencing severe psychological distress. Results: We enrolled 20 participants (59% of those screened) between January 2024 and April 2025, of which 17 began and 13/17 (76%) completed the intervention. Participants were 40–84 years old, 53% female, and 82% had cancer. There were no serious adverse events reported, and nine mild or moderate adverse events. Four participants withdrew due to disease progression or poor response. Of the 13 remaining participants, nine (69%) reported a meaningful global improvement (Patient Global Impression of Change ⩾ 5); 8 (62%) reported >50% improvement in Hamilton Depression Rating Scale scores, 7 (54%) reported >50% improvement in Hospital Anxiety and Depression Scale scores and 9 (72%) reported a meaningful improvement in Demoralization Scale II scores. Conclusions: Microdose psilocybin is a safe, feasible and potentially efficacious treatment for psychological distress in people with advanced illness.
- 30 January 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (4) , 514-523
Open AccessPSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial
Background: Psychological distress is a common problem near the end of life, for which we lack effective, timely and scalable treatments. No previous study has assessed whether microdose psilocybin can improve symptoms in this population. Aim: To determine whether microdose psilocybin is safe, feasible and potentially efficacious in a palliative setting. Design: Open label, single-arm clinical trial of a 3-week oral psilocybin intervention, starting with 1 mg daily in week 1, increased to 2 mg in week 2 and 3 mg in week 3. ClinicalTrials.gov NCT04754061. Setting/participants: Two-center study in Ottawa, Canada of adults with advanced, incurable illness and an estimated prognosis of 1–12 months, experiencing severe psychological distress. Results: We enrolled 20 participants (59% of those screened) between January 2024 and April 2025, of which 17 began and 13/17 (76%) completed the intervention. Participants were 40–84 years old, 53% female, and 82% had cancer. There were no serious adverse events reported, and nine mild or moderate adverse events. Four participants withdrew due to disease progression or poor response. Of the 13 remaining participants, nine (69%) reported a meaningful global improvement (Patient Global Impression of Change ⩾ 5); 8 (62%) reported >50% improvement in Hamilton Depression Rating Scale scores, 7 (54%) reported >50% improvement in Hospital Anxiety and Depression Scale scores and 9 (72%) reported a meaningful improvement in Demoralization Scale II scores. Conclusions: Microdose psilocybin is a safe, feasible and potentially efficacious treatment for psychological distress in people with advanced illness.
- Open Access
- 1 November 2025
- Published by SAGE Publications in Palliative Care and Social Practice
- Vol. 19
Connecting communities across the globe: Atlas protocol
Background: Providing universal access to palliative care is increasingly recognised as a global public health priority, especially in low- and middle-income countries. Compassionate communities could help with provision by fostering community-led responses to dying, death and grief. Despite their global growth, compassionate communities are often absent from national and international palliative care strategies, and few are represented in academic literature. This, along with their diversity and community-defined nature, can contribute to difficulties in documentation, evaluation and visibility, limiting the ability to showcase their benefits, form partnerships and evaluate practice. Objectives: This study protocol outlines the development of the first global atlas of compassionate communities, aiming to map their locations and increase understanding of their structures, activities and impacts. Design: A participatory methodology was used. This enabled global participants to complete and share the survey based on their experiences with community programmes addressing serious illness, dying and grief. A diverse steering committee guided the design, validation and piloting of the survey to ensure clarity, cultural sensitivity and accessibility. Eighteen global experts contributed to developing and validating the survey, with 14 of 15 items meeting the Content Validity Index threshold. The final survey captures data on location, aims, evaluation, challenges and impact. Dissemination involves global networks, social media and snowball sampling. Discussion: This protocol addresses a critical gap in Public Health Palliative Care literature by providing an inclusive and participatory method to map the compassionate community’s landscape. The resulting data will promote visibility, partnerships and future research, supporting greater recognition of global compassionate communities and their contributions to primary palliative care.
- 1 November 2025
- Published by SAGE Publications in Palliative Care and Social Practice
- Vol. 19
Open AccessConnecting communities across the globe: Atlas protocol
Background: Providing universal access to palliative care is increasingly recognised as a global public health priority, especially in low- and middle-income countries. Compassionate communities could help with provision by fostering community-led responses to dying, death and grief. Despite their global growth, compassionate communities are often absent from national and international palliative care strategies, and few are represented in academic literature. This, along with their diversity and community-defined nature, can contribute to difficulties in documentation, evaluation and visibility, limiting the ability to showcase their benefits, form partnerships and evaluate practice. Objectives: This study protocol outlines the development of the first global atlas of compassionate communities, aiming to map their locations and increase understanding of their structures, activities and impacts. Design: A participatory methodology was used. This enabled global participants to complete and share the survey based on their experiences with community programmes addressing serious illness, dying and grief. A diverse steering committee guided the design, validation and piloting of the survey to ensure clarity, cultural sensitivity and accessibility. Eighteen global experts contributed to developing and validating the survey, with 14 of 15 items meeting the Content Validity Index threshold. The final survey captures data on location, aims, evaluation, challenges and impact. Dissemination involves global networks, social media and snowball sampling. Discussion: This protocol addresses a critical gap in Public Health Palliative Care literature by providing an inclusive and participatory method to map the compassionate community’s landscape. The resulting data will promote visibility, partnerships and future research, supporting greater recognition of global compassionate communities and their contributions to primary palliative care.
- Open Access
- 16 June 2025
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 28 (6) , 769-778
Palliative Care Involvement and End-of-Life Care Intensity Among Adolescents and Young Adults with Nonmalignant Illnesses: A Population-Based Cohort Study in Ontario, Canada
Background: Adolescents and young adults (AYAs) with life-limiting illnesses face unique challenges and often receive late or no palliative care (PC). This study examines the correlation between PC involvement and the intensity of end-of-life care among AYAs with nonmalignant life-limiting illnesses. Design: A retrospective cohort study analyzing population-based health care data from 2010 to 2018. Setting/Subjects: The study population included AYAs aged 15–39 who died in Ontario, Canada, from nonmalignant life-limiting illnesses during the study period ( n = 2313). Measurements: PC involvement was defined as at least one encounter with a PC provider. End-of-life (EOL) care intensity was measured using rates of emergency department visits, hospitalizations, intensive care unit admissions, and mechanical ventilation in the last 30 days of life. Results: Of the 2313 AYAs studied, 37.5% had at least one PC encounter during their lifetime. Specialist PC delivered ≥90 days before death was associated with lower intensity of EOL care, including fewer intensive care unit deaths (17% vs. 34% versus 31%, p < 0.0001) and emergency department visits (17% vs. 27% versus 21%, p = 0.0091) when compared to generalist PC and no PC, respectively. Conclusions: AYAs with nonmalignant illnesses received high EOL care intensity and had a high percentage of death in acute care settings. Specialist PC involvement was associated with improved EOL care outcomes compared with generalist and no PC.
- 16 June 2025
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 28 (6) , 769-778
Open AccessPalliative Care Involvement and End-of-Life Care Intensity Among Adolescents and Young Adults with Nonmalignant Illnesses: A Population-Based Cohort Study in Ontario, Canada
Background: Adolescents and young adults (AYAs) with life-limiting illnesses face unique challenges and often receive late or no palliative care (PC). This study examines the correlation between PC involvement and the intensity of end-of-life care among AYAs with nonmalignant life-limiting illnesses. Design: A retrospective cohort study analyzing population-based health care data from 2010 to 2018. Setting/Subjects: The study population included AYAs aged 15–39 who died in Ontario, Canada, from nonmalignant life-limiting illnesses during the study period ( n = 2313). Measurements: PC involvement was defined as at least one encounter with a PC provider. End-of-life (EOL) care intensity was measured using rates of emergency department visits, hospitalizations, intensive care unit admissions, and mechanical ventilation in the last 30 days of life. Results: Of the 2313 AYAs studied, 37.5% had at least one PC encounter during their lifetime. Specialist PC delivered ≥90 days before death was associated with lower intensity of EOL care, including fewer intensive care unit deaths (17% vs. 34% versus 31%, p < 0.0001) and emergency department visits (17% vs. 27% versus 21%, p = 0.0091) when compared to generalist PC and no PC, respectively. Conclusions: AYAs with nonmalignant illnesses received high EOL care intensity and had a high percentage of death in acute care settings. Specialist PC involvement was associated with improved EOL care outcomes compared with generalist and no PC.
- 10 June 2025
- Published by BMJ in Journal of Medical Ethics
Physicians’ preferences for their own end of life: a comparison across North America, Europe, and Australia
Objective To study physicians’ personal preferences for end-of-life practices, including life-sustaining and life-shortening practices, and the factors that influence preferences. Design A cross-sectional survey (May 2022–February 2023). Setting Eight jurisdictions: Belgium, Italy, Canada, USA (Oregon, Wisconsin, and Georgia), Australia (Victoria and Queensland). Participants Three physician types: general practitioners, palliative care physicians, and other medical specialists. Main outcome measures Percentage of physicians who preferred various end-of-life practices and provided information about influence on preferences and demographics. Results 1157 survey responses were analysed. Physicians rarely considered life-sustaining practices a (very) good option (in cancer and Alzheimer’s respectively: cardiopulmonary resuscitation, 0.5% and 0.2%; mechanical ventilation, 0.8% and 0.3%; tube feeding, 3.5% and 3.8%). About half of physicians considered euthanasia a (very) good option (respectively, 54.2% and 51.5%). The proportion of physicians considering euthanasia a (very) good option ranged from 37.9% in Italy to 80.8% in Belgium (cancer scenario), and 37.4% in Georgia, USA to 67.4% in Belgium (Alzheimer’s scenario). Physicians practising in a jurisdiction with a legal option for both euthanasia and physician-assisted suicide were more likely to consider euthanasia a (very) good option for both cancer (OR 3.1, 95% CI 2.2 to 4.4) and Alzheimer’s (OR 1.9, 95% CI 1.4 to 2.6). Conclusion Physicians largely prefer to intensify alleviation of symptoms at the end of life and avoid life-sustaining techniques. In a scenario of advanced cancer or Alzheimer’s disease, over half of physicians prefer assisted dying. Considerable preference variation exists across jurisdictions, and preferences for assisted dying seem to be impacted by the legalisation of assisted dying within jurisdictions.
- 10 June 2025
- Published by BMJ in Journal of Medical Ethics
Physicians’ preferences for their own end of life: a comparison across North America, Europe, and Australia
Objective To study physicians’ personal preferences for end-of-life practices, including life-sustaining and life-shortening practices, and the factors that influence preferences. Design A cross-sectional survey (May 2022–February 2023). Setting Eight jurisdictions: Belgium, Italy, Canada, USA (Oregon, Wisconsin, and Georgia), Australia (Victoria and Queensland). Participants Three physician types: general practitioners, palliative care physicians, and other medical specialists. Main outcome measures Percentage of physicians who preferred various end-of-life practices and provided information about influence on preferences and demographics. Results 1157 survey responses were analysed. Physicians rarely considered life-sustaining practices a (very) good option (in cancer and Alzheimer’s respectively: cardiopulmonary resuscitation, 0.5% and 0.2%; mechanical ventilation, 0.8% and 0.3%; tube feeding, 3.5% and 3.8%). About half of physicians considered euthanasia a (very) good option (respectively, 54.2% and 51.5%). The proportion of physicians considering euthanasia a (very) good option ranged from 37.9% in Italy to 80.8% in Belgium (cancer scenario), and 37.4% in Georgia, USA to 67.4% in Belgium (Alzheimer’s scenario). Physicians practising in a jurisdiction with a legal option for both euthanasia and physician-assisted suicide were more likely to consider euthanasia a (very) good option for both cancer (OR 3.1, 95% CI 2.2 to 4.4) and Alzheimer’s (OR 1.9, 95% CI 1.4 to 2.6). Conclusion Physicians largely prefer to intensify alleviation of symptoms at the end of life and avoid life-sustaining techniques. In a scenario of advanced cancer or Alzheimer’s disease, over half of physicians prefer assisted dying. Considerable preference variation exists across jurisdictions, and preferences for assisted dying seem to be impacted by the legalisation of assisted dying within jurisdictions.
- Open Access
- 13 December 2024
- Published by SAGE Publications in Palliative Medicine
- Vol. 39 (2) , 266-276
Associations between physicians’ personal preferences for end-of-life decisions and their own clinical practice: PROPEL survey study in Europe, North America, and Australia
Background: Physicians have significant influence on end-of-life decisions. Therefore, it is important to understand the connection between physicians’ personal end-of-life care preferences and clinical practice, and whether there is congruence between what they prefer for themselves and for patients. Aim: Study to what extent physicians believe their personal end-of-life preferences impact their clinical practice and to what extent physicians’ personal treatment option preferences differ from what they prefer for their patients. Design: A cross-sectional survey was conducted from May 2022 to February 2023. Setting/participants: Eight jurisdictions: Belgium, Italy, Canada, USA (Oregon, Wisconsin, and Georgia), and Australia (Victoria and Queensland). Three physician types were included: general practitioners, palliative care physicians, and other medical specialists. Results: We analyzed 1157 survey responses. Sixty-two percent of physicians acknowledge considering their own preferences when caring for patients at the end of life and 29.7% believe their personal preferences impact the recommendations they make. Palliative care physicians are less likely to consider their own preferences when caring for and making recommendations to patients. Congruence was found between what physicians prefer for patients and themselves with cardiopulmonary resuscitation considered “not a good option for both” by 99.1% of physicians. Incongruence was found with physicians considering some options “not good for the patient, but good for themselves”—palliative sedation (8.3%), physician-assisted suicide (7.0%), and euthanasia (11.6%). Conclusion: Physicians consider their own preferences when providing care and their preferences impact the recommendations they make to patients. Incongruence exists between what physicians prefer for themselves and what they prefer for patients.
- 13 December 2024
- Published by SAGE Publications in Palliative Medicine
- Vol. 39 (2) , 266-276
Open AccessAssociations between physicians’ personal preferences for end-of-life decisions and their own clinical practice: PROPEL survey study in Europe, North America, and Australia
Background: Physicians have significant influence on end-of-life decisions. Therefore, it is important to understand the connection between physicians’ personal end-of-life care preferences and clinical practice, and whether there is congruence between what they prefer for themselves and for patients. Aim: Study to what extent physicians believe their personal end-of-life preferences impact their clinical practice and to what extent physicians’ personal treatment option preferences differ from what they prefer for their patients. Design: A cross-sectional survey was conducted from May 2022 to February 2023. Setting/participants: Eight jurisdictions: Belgium, Italy, Canada, USA (Oregon, Wisconsin, and Georgia), and Australia (Victoria and Queensland). Three physician types were included: general practitioners, palliative care physicians, and other medical specialists. Results: We analyzed 1157 survey responses. Sixty-two percent of physicians acknowledge considering their own preferences when caring for patients at the end of life and 29.7% believe their personal preferences impact the recommendations they make. Palliative care physicians are less likely to consider their own preferences when caring for and making recommendations to patients. Congruence was found between what physicians prefer for patients and themselves with cardiopulmonary resuscitation considered “not a good option for both” by 99.1% of physicians. Incongruence was found with physicians considering some options “not good for the patient, but good for themselves”—palliative sedation (8.3%), physician-assisted suicide (7.0%), and euthanasia (11.6%). Conclusion: Physicians consider their own preferences when providing care and their preferences impact the recommendations they make to patients. Incongruence exists between what physicians prefer for themselves and what they prefer for patients.
- Open Access
- 14 March 2024
- Published by SAGE Publications in Palliative Medicine
- Vol. 38 (4) , 485-491
Accelerated transcranial magnetic stimulation for psychological distress in advanced cancer: A phase 2a feasibility and preliminary efficacy clinical trial
Background: Psychological and existential suffering affects many people with advanced illness, and current therapeutic options have limited effectiveness. Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective therapy for refractory depression, but no previous study has used rTMS to treat psychological or existential distress in the palliative setting. Aim: To determine whether a 5-day course of “accelerated” rTMS is feasible and can improve psychological and/or existential distress in a palliative care setting. Design: Open-label, single arm, feasibility, and preliminary efficacy study of intermittent theta-burst stimulation to the left dorsolateral prefrontal cortex, 600 pulses/session, 8 sessions/day (once per hour) for 5 days. The outcomes were the rates of recruitment, completion of intervention, and follow-up (Feasibility); and the proportion of participants achieving 50% improvement on the Hamilton Depression Rating Scale (HDRS) or Hospital Anxiety and Depression Scale (HADS) 2 weeks post-treatment (Preliminary Efficacy). Setting/participants: Adults admitted to our academic Palliative Care Unit with advanced illness, life expectancy >1 month and psychological distress. Results: Due to COVID-19 pandemic-related interruptions, a total of nine participants were enrolled between August 2021 and April 2023. Two withdrew before starting rTMS, one stopped due to clinical deterioration unrelated to rTMS, and six completed the rTMS treatment. Five of six participants had a >50% improvement in HDRS, HADS-Anxiety, or both between baseline and the 2 week follow up; the sixth died prior to the 2-week follow-up. In this small sample, mean depression scores decreased from baseline to 2 weeks post-treatment (HDRS 18 vs 7, p = 0.03). Side effects of rTMS included transient mild scalp discomfort. Conclusions: Accelerated rTMS improved symptoms of depression, anxiety, or both in this small feasibility and preliminary efficacy study. A larger, sham-controlled study is warranted to determine whether rTMS could be an effective, acceptable, and scalable treatment in the palliative setting. Trial registration: NCT04257227
- 14 March 2024
- Published by SAGE Publications in Palliative Medicine
- Vol. 38 (4) , 485-491
Open AccessAccelerated transcranial magnetic stimulation for psychological distress in advanced cancer: A phase 2a feasibility and preliminary efficacy clinical trial
Background: Psychological and existential suffering affects many people with advanced illness, and current therapeutic options have limited effectiveness. Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective therapy for refractory depression, but no previous study has used rTMS to treat psychological or existential distress in the palliative setting. Aim: To determine whether a 5-day course of “accelerated” rTMS is feasible and can improve psychological and/or existential distress in a palliative care setting. Design: Open-label, single arm, feasibility, and preliminary efficacy study of intermittent theta-burst stimulation to the left dorsolateral prefrontal cortex, 600 pulses/session, 8 sessions/day (once per hour) for 5 days. The outcomes were the rates of recruitment, completion of intervention, and follow-up (Feasibility); and the proportion of participants achieving 50% improvement on the Hamilton Depression Rating Scale (HDRS) or Hospital Anxiety and Depression Scale (HADS) 2 weeks post-treatment (Preliminary Efficacy). Setting/participants: Adults admitted to our academic Palliative Care Unit with advanced illness, life expectancy >1 month and psychological distress. Results: Due to COVID-19 pandemic-related interruptions, a total of nine participants were enrolled between August 2021 and April 2023. Two withdrew before starting rTMS, one stopped due to clinical deterioration unrelated to rTMS, and six completed the rTMS treatment. Five of six participants had a >50% improvement in HDRS, HADS-Anxiety, or both between baseline and the 2 week follow up; the sixth died prior to the 2-week follow-up. In this small sample, mean depression scores decreased from baseline to 2 weeks post-treatment (HDRS 18 vs 7, p = 0.03). Side effects of rTMS included transient mild scalp discomfort. Conclusions: Accelerated rTMS improved symptoms of depression, anxiety, or both in this small feasibility and preliminary efficacy study. A larger, sham-controlled study is warranted to determine whether rTMS could be an effective, acceptable, and scalable treatment in the palliative setting. Trial registration: NCT04257227
- Open Access
- 16 January 2024
- Published by SAGE Publications in Palliative Medicine
- Vol. 38 (2) , 264-271
Long-term bereavement outcomes in family members of those who died in acute care hospitals before and during the first wave of COVID-19: A cohort study
Background: Severe grief is highly distressing and prevalent up to 1 year post-death among people bereaved during the first wave of COVID-19, but no study has assessed changes in grief severity beyond this timeframe. Aim: Understand the trajectory of grief during the pandemic by reassessing grief symptoms in our original cohort 12–18 months post-death. Design: Prospective matched cohort study. Settings/participants: Family members of decedents who died in an acute care hospital between November 1, 2019 and August 31, 2020 in Ottawa, Canada. Family members of patients who died of COVID (COVID +ve) were matched 2:1 with those who died of non-COVID illness (COVID −ve) during pandemic wave 1 or immediately prior to its onset (pre-COVID). Grief was assessed using the Inventory of Complicated Grief (ICG). Results: Follow-up assessment was completed by 92% (111/121) of family members in the initial cohort. Mean ICG score on the 12–18-month assessment was 19.9 (SD = 11.8), and severe grief (ICG > 25) was present in 28.8% of participants. One-third (33.3%) had either a persistently high (>25) or worsening ICG score (⩾4-point increase between assessments). Using a modified Poisson regression analysis, persistently high or worsening ICG scores were associated with endotracheal intubation in the deceased, but not cause of death (COVID +ve, COVID −ve, pre-COVID) or physical presence of the family member in the final 48 h of life. Conclusions: Severe grief is a substantial source of psychological morbidity in the wake of the COVID-19 pandemic, persisting more than a year post-death. Our findings highlight an acute need for effective and scalable means of addressing severe grief.
- 16 January 2024
- Published by SAGE Publications in Palliative Medicine
- Vol. 38 (2) , 264-271
Open AccessLong-term bereavement outcomes in family members of those who died in acute care hospitals before and during the first wave of COVID-19: A cohort study
Background: Severe grief is highly distressing and prevalent up to 1 year post-death among people bereaved during the first wave of COVID-19, but no study has assessed changes in grief severity beyond this timeframe. Aim: Understand the trajectory of grief during the pandemic by reassessing grief symptoms in our original cohort 12–18 months post-death. Design: Prospective matched cohort study. Settings/participants: Family members of decedents who died in an acute care hospital between November 1, 2019 and August 31, 2020 in Ottawa, Canada. Family members of patients who died of COVID (COVID +ve) were matched 2:1 with those who died of non-COVID illness (COVID −ve) during pandemic wave 1 or immediately prior to its onset (pre-COVID). Grief was assessed using the Inventory of Complicated Grief (ICG). Results: Follow-up assessment was completed by 92% (111/121) of family members in the initial cohort. Mean ICG score on the 12–18-month assessment was 19.9 (SD = 11.8), and severe grief (ICG > 25) was present in 28.8% of participants. One-third (33.3%) had either a persistently high (>25) or worsening ICG score (⩾4-point increase between assessments). Using a modified Poisson regression analysis, persistently high or worsening ICG scores were associated with endotracheal intubation in the deceased, but not cause of death (COVID +ve, COVID −ve, pre-COVID) or physical presence of the family member in the final 48 h of life. Conclusions: Severe grief is a substantial source of psychological morbidity in the wake of the COVID-19 pandemic, persisting more than a year post-death. Our findings highlight an acute need for effective and scalable means of addressing severe grief.
- Open Access
- 30 April 2020
- Published by Springer Nature in BMC Palliative Care
- Vol. 19 (1) , 1-13
Severe pain at the end of life: a population-level observational study
Background: Pain is a prevalent symptom at the end of life and negatively impacts quality of life. Despite this, little population level data exist that describe pain frequency and associated factors at the end of life. The purpose of this study was to explore the prevalence of clinically significant pain at the end of life and identify predictors of increased pain. Methods: Retrospective population-level cohort study of all decedents in Ontario, Canada, from April 1, 2011 to March 31, 2015 who received a home care assessment in the last 30 days of life (n = 20,349). Severe daily pain in the last 30 days of life using linked Ontario health administrative databases. Severe pain is defined using a validated pain scale combining pain frequency and intensity: daily pain of severe intensity. Results: Severe daily pain was reported in 17.2% of 20,349 decedents. Increased risk of severe daily pain was observed in decedents who were female, younger and functionally impaired. Those who were cognitively impaired had a lower risk of reporting pain. Disease trajectory impacted pain; those who died of a terminal illness (i.e. cancer) were more likely to experience pain than those with frailty (odds ratio 1.66). Conclusion: Pain is a common fear of those contemplating end of life, but severe pain is reported in less than 1 in 5 of our population in the last month of life. Certain subpopulations may be more likely to report severe pain at the end of life and may benefit from earlier palliative care referral and intervention.
- 30 April 2020
- Published by Springer Nature in BMC Palliative Care
- Vol. 19 (1) , 1-13
Open AccessSevere pain at the end of life: a population-level observational study
Background: Pain is a prevalent symptom at the end of life and negatively impacts quality of life. Despite this, little population level data exist that describe pain frequency and associated factors at the end of life. The purpose of this study was to explore the prevalence of clinically significant pain at the end of life and identify predictors of increased pain. Methods: Retrospective population-level cohort study of all decedents in Ontario, Canada, from April 1, 2011 to March 31, 2015 who received a home care assessment in the last 30 days of life (n = 20,349). Severe daily pain in the last 30 days of life using linked Ontario health administrative databases. Severe pain is defined using a validated pain scale combining pain frequency and intensity: daily pain of severe intensity. Results: Severe daily pain was reported in 17.2% of 20,349 decedents. Increased risk of severe daily pain was observed in decedents who were female, younger and functionally impaired. Those who were cognitively impaired had a lower risk of reporting pain. Disease trajectory impacted pain; those who died of a terminal illness (i.e. cancer) were more likely to experience pain than those with frailty (odds ratio 1.66). Conclusion: Pain is a common fear of those contemplating end of life, but severe pain is reported in less than 1 in 5 of our population in the last month of life. Certain subpopulations may be more likely to report severe pain at the end of life and may benefit from earlier palliative care referral and intervention.
- 6 February 2020
- Published by SAGE Publications in Journal of Applied Gerontology
- Vol. 40 (8) , 837-846
How Often, Where, and by Which Specialty Do Long-Term Care Home Residents Receive Specialist Physician Care? A Retrospective Cohort Study
This retrospective cohort study describes the rates, location, and determinants of specialist physician visits among 257,216 long-term care (LTC) residents across 648 LTC homes in Ontario, Canada, between 2007 and 2016. Visit rates in the last year of life were calculated for a sub-cohort of residents who died in LTC between 2013 and 2016. Visits were measured per resident-year using physician billings. Over 10 years, the rate of visits to specialists outside the LTC home was consistently higher than within LTC (2.99 vs. 1.55 visits/resident-year). Residents were less likely to receive specialist care if they were older, had dementia, or lived in urban LTC homes. From 12 months before death to the last week of life, rates of specialist visits increased by 246% and 56% inside and outside of LTC, respectively. Improving access to physician specialist care in LTC homes may reduce burdensome transitions and improve resident quality of life.
- 6 February 2020
- Published by SAGE Publications in Journal of Applied Gerontology
- Vol. 40 (8) , 837-846
How Often, Where, and by Which Specialty Do Long-Term Care Home Residents Receive Specialist Physician Care? A Retrospective Cohort Study
This retrospective cohort study describes the rates, location, and determinants of specialist physician visits among 257,216 long-term care (LTC) residents across 648 LTC homes in Ontario, Canada, between 2007 and 2016. Visit rates in the last year of life were calculated for a sub-cohort of residents who died in LTC between 2013 and 2016. Visits were measured per resident-year using physician billings. Over 10 years, the rate of visits to specialists outside the LTC home was consistently higher than within LTC (2.99 vs. 1.55 visits/resident-year). Residents were less likely to receive specialist care if they were older, had dementia, or lived in urban LTC homes. From 12 months before death to the last week of life, rates of specialist visits increased by 246% and 56% inside and outside of LTC, respectively. Improving access to physician specialist care in LTC homes may reduce burdensome transitions and improve resident quality of life.